The potential to uncouple the telomeric and pro-oncogenic activities of TRF2 [13] raises the possibility of pharmacologically downregulating TRF2, thus conferring multi-hit anti-cancer benefits without deleterious pro-aging side effects. Here, TERF2 is linked to cancer.